uniQure N.V. (NASDAQ:QURE) Director Rachelle Suzanne Jacques Sells 2,112 Shares

uniQure N.V. (NASDAQ:QURE - Get Free Report) Director Rachelle Suzanne Jacques sold 2,112 shares of uniQure stock in a transaction on Friday, June 20th. The shares were sold at an average price of $14.45, for a total transaction of $30,518.40. Following the completion of the transaction, the director now owns 28,346 shares in the company, valued at approximately $409,599.70. This trade represents a 6.93% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

uniQure Stock Up 1.9%

NASDAQ QURE traded up $0.27 on Tuesday, reaching $14.22. The company had a trading volume of 852,314 shares, compared to its average volume of 1,953,833. The firm has a market capitalization of $778.97 million, a PE ratio of -3.24 and a beta of 0.08. uniQure N.V. has a 1 year low of $3.73 and a 1 year high of $19.18. The firm has a 50-day moving average of $14.29 and a 200-day moving average of $13.99. The company has a debt-to-equity ratio of 1.53, a current ratio of 11.99 and a quick ratio of 11.99.

uniQure (NASDAQ:QURE - Get Free Report) last released its earnings results on Friday, May 9th. The biotechnology company reported ($0.82) EPS for the quarter, beating the consensus estimate of ($1.07) by $0.25. The company had revenue of $1.57 million during the quarter, compared to analysts' expectations of $5.93 million. uniQure had a negative return on equity of 483.87% and a negative net margin of 1,077.05%. On average, equities research analysts anticipate that uniQure N.V. will post -3.75 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have commented on QURE. HC Wainwright restated a "buy" rating and set a $70.00 target price on shares of uniQure in a research report on Thursday, May 29th. Wells Fargo & Company decreased their target price on shares of uniQure from $35.00 to $30.00 and set an "equal weight" rating on the stock in a research report on Friday, February 28th. Cantor Fitzgerald upgraded shares of uniQure to a "strong-buy" rating in a research report on Monday, May 19th. Chardan Capital reiterated a "buy" rating and issued a $38.00 price objective on shares of uniQure in a research report on Friday, May 30th. Finally, Guggenheim reiterated a "buy" rating and issued a $28.00 price objective on shares of uniQure in a research report on Monday, May 12th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, six have given a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, uniQure presently has an average rating of "Moderate Buy" and a consensus target price of $37.82.

Institutional Investors Weigh In On uniQure

Several large investors have recently added to or reduced their stakes in QURE. Twin Tree Management LP acquired a new position in shares of uniQure during the fourth quarter valued at $77,000. Mraz Amerine & Associates Inc. acquired a new position in shares of uniQure during the first quarter valued at $106,000. OMERS ADMINISTRATION Corp acquired a new position in shares of uniQure during the first quarter valued at $152,000. ADAR1 Capital Management LLC acquired a new position in shares of uniQure during the fourth quarter valued at $177,000. Finally, Wells Fargo & Company MN increased its holdings in shares of uniQure by 13.9% during the fourth quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company's stock valued at $217,000 after purchasing an additional 1,503 shares during the period. 78.83% of the stock is owned by institutional investors and hedge funds.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.